secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVANOS MEDICAL, INC. (AVNS)
CIK:        0001606498
Form:       8-K
Filed at:   2023-01-11T23:59:59+00:00
Accession:  0001606498-23-000011
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.05, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avanos launches 3-year transformation; CFO Greiner adds Chief Transformation Officer role; SVP Haydon to depart
--------------------------------------------------------------------------------

- Three-year plan: combine Chronic Care & Pain franchises, exit low-margin products, cost management, and focused M&A.
- CFO Michael Greiner assumes additional role of Chief Transformation Officer to lead the transformation.
- Kerr Holbrook appointed SVP & Chief Commercial Officer, overseeing combined commercial organization.
- William D. Haydon, SVP & GM Pain Franchise, to depart March 31, 2023; receives $972K severance plus up to $300K transition bonus.
- Company currently unable to estimate total transformation costs; will file amended 8-K within four business days.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1606498/000160649823000011/0001606498-23-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1606498/000160649823000011/avns-20230110.htm
  HTML page:      https://secwatch.observer/filing/0001606498-23-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer